olive oil and atrial fibrillation

another article came out of the PREDIMED study (prevention with mediterranean diet study), where 6705 people without prevalent afib were randomly assigned to one of 3 diets: mediterranean diet supplemented with extra-virgin olive oil, mediterranean diet plus mixed nuts, or control group (low fat diet). in this post-hoc analysis they looked at the development of atrial fibrillation (see afib olive oil dec risk circ 2014 in dropbox, or DOI: 10.1161/CIRCULATIONAHA.113.006921). [i sent out blog on 1/9/14 on primary CAD prevention and one on 1/8/14 on diabetes prevention from this study -- i appended excerpts below since they give details of diet]. the findings in the current study were:

    --new cases of afib, after 4.7 years:
        --med diet with supplemented extra-virgin olive oil: 72 cases, afib rate of 6.8 per 1000 person-years (and, there was a dose-response curve with higher olive oil consumption=less afib)
        --med diet with supplemented mixed nuts: 82 cases, afib rate of 9.9 per 1000 person-years
        --control diet: 92 new cases, afib rate of 10.1 per 1000 person-years
    --so, HR of atrial fibrillation with extra-virgin olive oil vs control group was 0.62 (CI 0.45-0.85). non-significant diff between mixed nuts and control group (HR 0.89 with CI 0.65-1.20)
 unclear why atrial fibrillation is decreased with olive oil. but, extra-virgin olive oil is known to have anti-inflammatory effects and reduces oxidative stress in patients with metabolic syndrome.  there is argument in the literature that these factors are important in the development of afib (higher CRP or IL-6 levels assoc with development of afib. same with markers of oxidative stress). 


limitations of study above include that afib was not the primary endpoint of the study (CAD, stroke were), and spanish study with mostly older white people at high cardiovascular risk, limiting potential generalizability. overall, i think that extra-virgin olive oil has pretty profound protective vascular effects, but i would caution about extrapolating this result in a reductionist way. the olive oil was consumed in the context of an overall healthy diet (Mediterranean diet) and seemed to add benefit. assuming that frying chicken with breadcrumbs in extra-virgin olive oil and then sprinkling the potato chips with a little more may not have the same positive benefit.....

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

HDL a negative risk factor? or cholesterol efflux??

Although the data on HDL being protective of atherosclerotic disease is pretty consistent, there are negative studies, and the data on medications which dramatically improve HDL levels (eg, the cholesteryl ester transfer protein --CETP --inhibitors, such as torcetrapib) are clinically disappointing. there have been several explanations for this. for example, some HDL particles are "pro-inflammatory" and elicit an atherosclerotic response (which may be related to apolipoprotein C-III). a new article in NEJM highlights another angle -- that the issue is not the HDL number, but HDL's functionality in the reverse transport of cholesterol, as measured by the cholesterol efflux capacity (see  lipids HDL efflux capacity vs amt NEJM 2014 in dropbox, or  DOI: 10.1056/NEJMoa1409065). This article looks at the Dallas Heart Study, where they measured HDL levels, HDL particle concentrations, and cholesterol efflux capacity in 2924 adults free of cardiovascular disease and followed p
Read more

Drug company shenanigans: narcolepsy drug

I have not done a blog for a long time on drug company shenanigans. So it is my great pleasure to bring up a brand-new drug company approach to garner huge amounts of money (see  https://www.nytimes.com/2023/02/28/business/jazz-narcolepsy-avadel-patents.html?smid=nytcore-ios-share&referringSource=articleShare  ).  Based on an article by  Rebecca Robbins of the New York Times, who has written several articles on drug company excesses   As background, this will be my 42 nd  such blog: for the array, see  https://bucommunitymed.wpengine.com/page/4/?s=drug+company+shenanigans   Th e drug company  approach  this time  to extending  their  patents has a few “interesting” angles: -- this is a medication manufactured by Jazz Pharmaceuticals to treat narcolepsy: there are 2 versions: Xyrem and Xywav (Xywav has less sodium, so is marketed to those who should be on a low sodium diet). These meds are basically derivatives of gammahydroxybutyric acid (GHB)      -- the drug actually has a pretty
Read more

UPDATE: ASCVD risk factor critique

  I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:              -- there is very clear evidence that there are many individual risk factors that are associated with increased risk of a cardiovascu
Read more